Literature DB >> 21924920

May intra-operative radiotherapy have a role in the treatment of prostate cancer?

Marco Krengli1, Carlo Terrone, Barbara Alicja Jereczek-Fossa, Debora Beldì, Roberto Orecchia.   

Abstract

Treatment of locally advanced prostate cancer is still a challenge. Combined treatments including hormone therapy, radiotherapy, and/or surgery can achieve less than 50% of disease free survival at 10 years. Almost 50% of patients with locally advanced disease after radical prostatectomy experience local relapse and biochemical failure occurs up to 70% of cases after radiotherapy and hormone therapy. Postoperative radiotherapy has recently demonstrated to improve biochemical and clinical outcome in pT3 and/or positive margin tumors in 3 large randomized trials. Therefore, combining surgery and intra-operative radiotherapy (IORT) might be of value in this patient population. Recently, a number of studies have shown the feasibility of IORT, delivered with dedicated linear accelerators, combined or not with external beam radiotherapy with the aim of improving clinical outcome and possibly shortening overall treatment time. Preliminary clinical results look encouraging and could be the premise for future controlled prospective phase III trials.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21924920     DOI: 10.1016/j.critrevonc.2011.08.007

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  2 in total

1.  Identification of men with the highest risk of early disease recurrence after radical prostatectomy.

Authors:  Debasish Sundi; Vinson Wang; Phillip M Pierorazio; Misop Han; Alan W Partin; Phuoc T Tran; Ashley E Ross; Trinity J Bivalacqua
Journal:  Prostate       Date:  2014-01-22       Impact factor: 4.104

2.  Clinical and technical characteristics of intraoperative radiotherapy. Analysis of the ISIORT-Europe database.

Authors:  M Krengli; F A Calvo; F Sedlmayer; C V Sole; G Fastner; M Alessandro; S Maluta; R Corvò; E Sperk; M Litoborski; C Pisani; C Fillini; F Fusconi; M F Osti; L Tomio; H Marsiglia; A Ciabattoni; W Polkowski; A Di Grazia; A Gava; A Kuten; C Iotti; C Gonzalez; M Sallabanda; J-B Dubois; G Catalano; V Valentini
Journal:  Strahlenther Onkol       Date:  2013-07-12       Impact factor: 3.621

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.